TetraQ is the first contract research organisation in Australia to provide integrated preclinical services to the global pharmaceutical and biotechnology industries. For a summary of TetraQ's view of integrated drug development, see the TetraQ Drug Development Roadmap.

TetraQ provides a broad range of preclinical services and advice to companies that are in the early stages of drug development and can assist in bridging the gap between drug discovery and early stage clinical trials. They take the time to understand your business needs to provide comprehensive and tailored solutions at a competitive rate, either in-house or through their extensive network.

TetraQ draws on the expertise of four leading specialists in preclinical drug development. their team of highly experienced scientists are supported by a dedicated Commercial Manager, Operations Manager, Sales & Services Manager and a Quality Assurance Manager.  TetraQ have appointed a North American Business Development Manager based in California and have recently announced a collaboration with Japanese clinical trial organisation, MORE Medical Inc, in a step to promote  TetraQ preclinical drug development services to Japanese biotech stakeholders.

TetraQ have built world-class facilities to provide an extensive and expanding range of services. This has been enabled by $8.1M in investment funds from the Queensland Government’s Smart State Research Facilities Fund, along with significant cash and in-kind support from The University of Queensland and its supporting partners, Q-Pharm Pty Ltd and The Queensland Institute of Medical Research.

Formed in 2005 and located at The University of Queensland (UQ) in Brisbane, TetraQ is the commercial arm of the Centre for Integrated Preclinical Drug Development. This Centre is the focal point of research and training excellence in the field of preclinical drug development. TetraQ is also a registered business of UniQuest Pty Ltd, the main technology transfer company of UQ.